mCRPC VL

Novel STEAP1 Targeted BiTE Therapy Demonstrates Early Efficacy in Phase 1 Trial - William Kevin Kelly

Details
Kevin Kelly discusses a groundbreaking approach to prostate cancer treatment with Alicia Morgans. He presents Xaluritamig (AMG 509) a novel bi-specific antibody targeting the STEAP1 protein, prevalent in prostate cancer cells. This innovative therapy, a form of biTE therapy, is designed to attract T-cells for targeted cytotoxicity. In a phase one trial involving advanced prostate cancer patients w...

New Medicare Data Compares Enzalutamide and Abiraterone Outcomes in mCRPC Patients - Dan George

Details
Zach Klaassen speaks with Dan George about a key study comparing Enzalutamide (Enza) and Abiraterone (Abi) in pre-chemotherapy metastatic castration-resistant prostate cancer (mCRPC). This study addresses a significant gap in head-to-head clinical trials for these drugs. Dr. George discusses various data sources, including the French National Database, Flatiron, and VA data, all indicating a survi...

Sequencing Therapies in Advanced Prostate Cancer Requires Balancing Many Factors - Rana McKay

Details
Alicia Morgans and Rana McKay delve into the complexities of treatment sequencing for metastatic castration-resistant prostate cancer. They highlight the expansive range of available therapies, including hormonal, targeted, immunotherapies, chemotherapy, and radioligand therapies. The focus is on the importance of patient involvement in decision-making, considering individual preferences, lifestyl...

Attacking Androgen Receptor From Two Sides: The Potential of a Novel Drug Duo in Prostate Cancer - Christos Kyriakopoulos

Details
Alicia Morgans interviews Christos Kyriakopoulos about a study presented at ESMO on EPI-7386, also known as masofaniten. Dr. Kyriakopoulos elaborates on this phase one-two study, which explores the combination of EPI-7386 with enzalutamide in patients with metastatic castration-resistant prostate cancer. EPI-7386 is novel in targeting the androgen receptor's N-terminal domain, differing from other...

The PSMAfore Trial and its Role in Shaping Future Prostate Cancer Treatments - Oliver Sartor

Details
In a discussion with Alicia Morgans, Oliver Sartor delves into the innovative PSMAfore trial, focusing on treating metastatic CRPC in taxane-naive patients using PSMA PET-positive lesions. This trial, evolving from the VISION trial, aims to expand treatment eligibility by initiating therapy before chemotherapy, addressing the fact that nearly half of metastatic prostate cancer patients never recei...

Exploring the Safety and Efficacy of EPI-7386 in Combination with Enzalutamide in mCRPC - Ronald Tutrone

Details
Zach Klaassen and Ron Tutrone explore the promising data surrounding EPI-7386, an inhibitor of the androgen receptor. The conversation focuses on the phase two trial of EPI-7386 in combination with enzalutamide for treating metastatic castrate-resistant prostate cancer. Dr. Tutrone explains the unique mechanism of action of EPI-7386, which targets the N-terminal domain of the androgen receptors, u...

Masofaniten in Advanced Prostate Cancer: A Phase II Trial and Promising Insights - Mark Markowski

Details
Medical Oncologists Alicia Morgans and Mark Markowski discuss challenges in treating advanced prostate cancer, related to the evolving resistance requiring novel mechanisms of action to give us new options for treatment. A new drug, masofaniten (formerly EPI-7386), is being studied in a phase II trial for metastatic castration-resistant prostate cancer (mCRPC). The trial aims to enroll 120 patient...

A VISION Substudy of Reader Agreement on 68Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for 177Lu-PSMA-617 Radioligand Therapy - Beyond the Abstract

Details
The pivotal phase 3 VISION study used [68Ga]Ga-PSMA-11 (also known as 68Ga-PSMA-11) imaging to identify patients with metastatic castration-resistant prostate cancer eligible for [177Lu]Lu-PSMA-617 radioligand therapy, based on predefined read criteria. In this substudy of VISION, the inter-reader variability and intra-reader reproducibility of visual assessments of 68Ga-PSMA-11 positron emission...

The ECLIPSE Trial: Investigating Lutetium-177 in the Pre-Chemotherapy Space in Advanced Prostate Cancer - Daniel Saltzstein

Details
Phillip Koo and Daniel Saltzstein delve into the ECLIPSE clinical trial. The trial, aiming to enroll over 400 patients, brings Lutetium-177, a radioligand therapy, to patients with metastatic castrate-resistant prostate cancer at an earlier stage than it's currently approved for. Dr. Saltzstein outlines the trial's inclusion criteria, notably patients with castrated testosterone, PSA progression,...

Impact of Previous Local Treatment on First-line Androgen Receptor Axis Targeted Therapy Response in mCRPC: A Secondary Analysis of the COU-AA-302 Trial - Soumyajit Roy

Details
Alicia Morgans interviews Soumyajit Roy regarding his work on the COU-AA-302 data set, published in European Urology. The study investigates the effects of definitive prostate treatments, such as radiation therapy or radical prostatectomy, on outcomes when patients with metastatic castrate-resistant prostate cancer (mCRPC) are treated with abiraterone. Dr. Roy explains his motivation for the study...